Abstract
and to enable scientific research to improve this method of treatment for patients with end-stage heart failure. The registry permits the retrieval of data on survival and morbidity rates so that clinicians and industry representatives can identify and learn from the factors that influence the results of MCS therapy. Various measures were taken to safeguard the completeness and correctness of the data that have been submitted by the participating centres to improve data quality. These methods include data input control, onsite audits and statistical analyses. Data have been made available for several studies that resulted in publications [1, 2] or abstracts [3] . Upon the request of the participating centres, custom analyses of data could be provided. Of special interest, a paediatric study group has been established among the EUROMACS members to carry out studies on the treatment of children with MCS. The first article containing paediatric data from the EUROMACS will be submitted in 2017 to the European Journal of Cardio-Thoracic Surgery (EJCTS). Several joint projects with other national and international registries to exchange or to accumulate data were initiated. Finally, a course for ventricular assist device (VAD) coordinators, including the EUROMACS registration modalities, has been conducted annually since 2015 [4] .
The EUROMACS and the International Society for Heart and Lung Transplantation (ISHLT) have an agreement whereby the ISHLT participates in the Interagency Registry for Mechanically Assisted Circulatory Support (IMACS). IMACS enrols and follows patients receiving durable MCS devices on a global basis. The first IMACS annual report, including data from EUROMACS, was published in the spring of 2016 [5] .
METHODS
Hospitals that contribute baseline and follow-up clinical data from their consenting patients to EUROMACS agree to do so within 6 weeks after the patient receives an MCS device. Similarly, events are to be registered within 6 weeks after their occurrence. Hospitals register their patients with MCS online via a secured Internet connection, using an individual password, in an ongoing prospective manner, but also retrospectively to 1 January 2011. Although some centres have chosen to submit earlier records, only implants from 1 January 2011 are included in this analysis, which is consistent with the data included in the first annual report [6] .
All paediatric and adult patients who received a long-term MCS device, designed for > _6 months support, were eligible for registration in the EUROMACS database (Table 1) . A provision has been made for devices that were implanted concomitantly (as a temporary right ventricular assist device) with a long-term device (see Table 1 , 'Short-term devices').
QUALITY CONTROL
To safeguard the correctness and completeness of the data submitted by the contributing hospitals, a set of tools and protocols has been developed. Primarily, the hospitals sign an agreement in which they consent to submit data from every patient who receives MCS on a long-term basis (support duration > _6 months), unless the patient refuses consent to participate. The procedure to obtain consent is based on national legislation, which varies in the different nations in which hospitals submitting data are situated. The hospitals agree to communicate data records to the registry in accordance with the structure of the EUROMACS database and ensure that all data have been correctly acquired, in accordance with the state of the art of medical procedures.
In addition, checks on data completeness and data consistency are carried out on a structural basis. Data managers are approached directly in case of specific issues. The participating hospitals are requested to confirm the completeness of their data on 30 June and 31 December each year. Thus, the consolidated data can be used for analyses and the annual report. For more details, see Supplementary Material.
On-site audits are conducted by the EUROMACS management team and comprise an overview of possible non-compliance reports using a random selection of patient files that are compared with the respective data files from the local hospitals.
Statistical analysis
In preparing the analysis for this report, we involved on-site data managers to achieve complete data with respect to the most important variables. Our goal was to increase the completeness of the survival data by assuming a patient's death if a date of death or a cause of death had been entered or if the patient's death was mentioned as an adverse event or as a type of discharge. We used the brand of the device to derive the type of pump in case this information was missing. No multiple data imputations were done. We checked for the chronological plausibility of the follow-up records and eliminated or corrected implausible records by queries to on-site data managers. The Kaplan-Meier estimates of cumulative probabilities were calculated for mortality, including 95% confidence intervals (CIs) as a measure of certainty, where we did not truncate the curves. A patient is considered at risk up to the date of his or her individual last follow-up information saying that the patient has received a transplant, has been weaned from the device, has died or is alive. For major adverse events other than death, we calculated event rates per 100 patient-months and constructed corresponding CIs that accounted for the Poisson distribution of event counts. Competing outcomes (ongoing device support or death or heart transplant or weaning) are presented for the first 6 months after device implant. Percentages are calculated as the ratio of the number of subjects who experienced the mentioned outcomes divided by the total number of subjects in the data set multiplied by 100. To avoid any censored individuals, only patients with a follow-up period of at least 6 months were considered for the competing outcome analysis. All CIs and P-values were 2-sided. All calculations were made using Stata 12 (Stata Corporation LLC, College Station, TX, USA).
RESULTS
Since the publication of the first EUROMACS annual report, the enrolment of hospitals increased by 148%, from 21 to 52, and patients in the registry more than tripled from 741 to 2681 (262%) [6] . Table 2 presents the 52 hospitals in 18 countries (in 2013, 21 hospitals in 12 countries) [6] contributing data to the EUROMACS as of 31 December 2016. On the same date, the agreement in which the rules of engagement were defined was under consideration in 4 hospitals in 2 additional countries. In addition, the Spanish Registry for Mechanical Circulatory Support (ESPAMACS), which includes the collective data from almost all Spanish hospitals that implant MCS devices, agreed to provide data to EUROMACS on a regular basis, whereas 1 hospital contributes its data separately [7] . At the end of 2015, an agreement was reached with the Societé Francaise de Chirurgie Thoracique et Cardio-Vasculaire (SFCTCV) [8] whereby the 18 hospitals in France that implant MSC devices will start contributing data in 2017.
Centres
EUROMACS, in turn, has come to an understanding with the ISHLT concerning its participation in IMACS.
Update per 31 December 2016
The analyses in this annual report are based on the data for implantation of MCS devices beginning 1 January 2011. Between 1 January 2011 and 31 December 2016, 2681 patients (mean age 51.7 years, median 55 years, range 0-86 years) were registered in the EUROMACS database (Table 3 ). The increase in the number of devices implanted, compared with the number in the first annual report, is 1856 (+225%).
The aetiology of heart failure was primarily ischaemic cardiomyopathy (n = 1091, 40.7%) and idiopathic cardiomyopathy (n = 926, 34.5%) ( Table 3 ). The distribution by ABO blood group type and gender is given in Table 4 . Table 5 presents the types of VADs implanted stratified according to age in 2681 patients for whom exact data were available.
An isolated left ventricular assist device (LVAD) was implanted in 2366 (88.3%) patients as a first implant. An LVAD with a temporary right ventricular assist device was implanted in 126 (4.7%) patients. Isolated right ventricular assist device s were implanted in 28 (1.0%) patients and total artificial hearts in 27 (1.0%) patients. Table 6 presents that, after the first implantation of MCS, 218 patients underwent a second device implantation and 37 patients received a third implantation, 9 patients a fourth implantation and 2 patients a fifth implantation.
Strategy for ventricular assist device implantations Table 7 presents the strategy for VAD implantations in 2947 implantations. VADs were implanted primarily as bridge to candidacy (possible bridge to transplant, n = 1052, 36%) or bridge to transplant (n = 813, 28%). VADs as a destination or a permanent therapy were implanted in 458 (16%) patients. We expected that, given the large numbers of patients on the heart transplant waiting lists in several countries, a relative increase would be seen in the number of patients older than 65 years on destination therapy compared to the numbers in other age categories [9] .
INTERMACS LEVELS
VAD implantation was performed primarily in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Levels 2 and 3 as presented in Table 8 . (28) 48 (14) 19 (10) 813 (28) Destination therapy 22 (2) 170 (12) 157 (47) 109 (60) 458 (16) Rescue therapy 68 (7) 105 (7) 19 (6) 18 (10) 
OUTCOME OF VENTRICULAR ASSIST DEVICE IMPLANTATION
Types of ventricular assist devices implanted Figure 1 shows the types of VADs implanted in both paediatric and adult patients from 1 January 2011 to 31 December 2016, entered into the EUROMACS database.
Survival
The overall survival of 2268 adult patients (aged >17 years) with a continuous LVAD or a biventricular assist device (BiVAD) and a mean follow-up period of 379 days (median 236 days, range 1-2098 days) was 86% (CI 85-88), 66% (CI 64-68), 53% (CI 51-56) and 42% (CI 39-45) at 30 days, 1 year, 2 years and 3 years, respectively (Fig. 2) . Stratified according to the site of VAD implantation, the survival rate of 2113 patients with continuous-flow LVAD, either as a destination therapy or as a bridge to transplant, was 88% (CI 87-90), 69% (CI 66-71), 55% (CI 52-58) and 44% (CI 40-47) at 30 days, 1 year, 2 years and 3 years, respectively (Fig. 3) . The survival rate of 141 patients with BiVAD was 61% (CI 52-68), 32% (CI 23-40), 27% (CI 19-35) and 21% (CI 13-30) at 30 days, 1 year, 2 years and 3 years, respectively (Fig. 3) . Figure 4 shows the age group-based survival rates of patients with primary LVAD and BiVAD support. At 2 years, the survival rate was 64% (CI 59-68), 53% (CI 49-56), 42% (CI 35-49) and 27% (CI 18-37) in patients aged <50, 50-64, 65-70 and >70 years, respectively. Figure 5 depicts the actuarial survival depending on device strategy. Bridge-to-transplant strategy revealed the best survival. Table 9 shows the causes of death of 1027 patients with VAD who were registered as deceased. The 2 main causes of death were multiorgan failure in 186 (18%) patients and infections and sepsis in 208 (20%) patients.
Adverse events (morbidity)
Major adverse events (Table 10) related to device malfunctions, such as accidental disconnection, wear or breaking of the driveline and pump thrombosis, were observed 454 times within the entire follow-up period, which corresponds to 0.037 malfunctions per patient year. For definitions of adverse events, we refer the reader to the corresponding INTERMACS definitions [10] . As other groups have reported, patients with continuous-flow assist devices had a higher risk for major bleeding [11] . In the EUROMACS database, major bleeding (requesting at least 1 unit of blood for transfusion) was reported 433 times, whereas 845 major infections caused by either the driveline or the assist device were observed. Neurological dysfunction (stroke) occurred in 319 of the adverse events, whereas 52 of the adverse events were a combination of one or more events. All major adverse events occurred more frequently within the first 3 months after implantation than later during the patients' course. The rate of device malfunctions and infections reached a stable state 1 year after implantation, whereas the rates of bleeding and neurological events decreased for the entire follow-up period.
Competing outcomes
Within 6 months after device implantation, 5.4% of the patients received a heart transplant and 27.9% died. Only 1.5% could be weaned from the device, and 65.2% had ongoing device support during this period (Fig. 6 ). 
DISCUSSION
Compared to the first EUROMACS report, the number of participating hospitals has increased from 21 to 52 (+148%), whereas the number of registered implantations more than tripled from 825 to 2947 (+257%). The 3-year survival rate of patients with continuous-flow LVAD and BiVAD implants, 44% and 21%, respectively, was far less favourable than the results of the seventh INTERMACS annual report ( fig. 6 of that report), which was 58% and 40%, respectively [12] . There are major differences between the rate of morbidity in our current EUROMACS report and recent INTERMACS results, such as the occurrence of major infections, which is far higher in the INTERMACS cohort within the first 3 months after implantation (15.19 vs 6.18 events per 100 patient-months) but lower during the later course (4.03 vs 5.49) [6] . The same pattern can be seen with respect to neurological events (4.18 vs 3.03 events per 100 patient-months within 3 months after implant, 1.21 vs 1.87 in the later course).
What are the possible explanations for differences? (i) One reason might be differences in the quality of the data with respect to the completeness of reported events. INTERMACS has a high level of completeness of collected data, mandated by the National Institutes of Health, though, similar to EUROMACS, INTERMACS has also periodic site visits, confirmation of case counts and frequent contact with sites to review adverse events (J.K. Kirklin, personal communication). On the other hand, EUROMACS, being an EACTS Committee, follows the same strategy of quality control as INTERMACS (see section 'Quality Control').
(ii) There might be some differences in definitions of events and different periods of observation times. (iii) There may be some real differences in outcomes related to different devices and management strategies or patient selection practices. These differences were discussed with IMACS before the 2 registries agreed to analyse aggregated anonymous EUROMACS data. An incoming study proposal intends to investigate the details of these differences. The growth in the number of participating hospitals precipitated the increase in quality control by means of statistical analyses.
Limitations
The registry continues recruiting to increase the numbers of contributing centres, the goal being to include as many European centres as possible. In contrast to the situation in the USA, participation in EUROMACS is not mandatory in Europe. Therefore, surveillance and improvement of data quality are ongoing efforts.
CONCLUSION
Because EUROMACS became an official committee of EACTS, the registry experienced an increase in the number of participating hospitals (+148%) and more than tripled the number of implants, representing European MCS data at the best achievable level and reached a unique comprehensive representation of European MCS baseline and follow-up data. In addition, the productive cooperation with IMACS permits the inclusion of worldwide data and important comparisons. Mortality and morbidity outcome data differ between the registries. It is of high importance to investigate the reasons for these differences.
